Stephen Wilson joins Cytocom to serve as head of global innovation
FORT COLLINS -- Cytocom, Inc . announced Stephen Wilson has joined the company as its head of global innovations, effective April 19. Wilson arrives at Cytocom after spending nearly 25... Read More
Wednesday April 21, 2021
Cytocom receives FDA clearance of IND for Phase 2 clinical trial of CYTO-205 as treatment for COVID-19
FORT COLLINS -- Cytocom, Inc. announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for a Phase 2 clinical trial to evaluate the safety... Read More
Thursday March 18, 2021
Cytocom in proposed merger with Cleveland BioLabs after SEC filing
FORT COLLINS/ BUFFALO, N.Y. -- New York-based Cleveland BioLabs, Inc. (NASDAQ: CBLI), a biopharmaceutical company developing novel approaches to activate the immune system, filed a registration... Read More
Thursday February 18, 2021
Cytocom updates investigational new drug application for phase 2 clinical trial of CYTO-205 for treatment of COVID-19
FORT COLLINS -- Cytocom, Inc. today provided an update regarding its CYTO-200 portfolio of clinical programs. Cytocom said it has submitted an Investigational New Drug (IND) application with... Read More
Tuesday February 16, 2021
IN Sponsors
Browse
Entrepreneurial by Nature
